Research Analysts Set Expectations for VYGR FY2029 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Voyager Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.86) per share for the year. Wedbush has a "Outperform" rating and a $9.00 price objective on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share.

VYGR has been the subject of a number of other research reports. Citigroup began coverage on shares of Voyager Therapeutics in a report on Monday, December 2nd. They issued a "buy" rating and a $12.00 price objective for the company. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research note on Monday, January 27th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research report on Friday, January 10th. They set an "overweight" rating and a $5.73 price objective for the company. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $15.72.

Voyager Therapeutics Stock Down 3.4 %

NASDAQ VYGR traded down $0.15 during trading on Thursday, hitting $4.23. The stock had a trading volume of 441,402 shares, compared to its average volume of 310,971. The company has a market capitalization of $231.08 million, a PE ratio of 5.96 and a beta of 0.91. The firm has a 50 day moving average price of $5.57 and a 200 day moving average price of $6.23. Voyager Therapeutics has a twelve month low of $4.00 and a twelve month high of $10.66.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC acquired a new position in Voyager Therapeutics in the fourth quarter valued at $29,000. Tower Research Capital LLC TRC boosted its position in shares of Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after purchasing an additional 3,077 shares during the period. Picton Mahoney Asset Management boosted its position in shares of Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock valued at $33,000 after purchasing an additional 2,444 shares during the period. Oxford Asset Management LLP acquired a new stake in shares of Voyager Therapeutics in the 4th quarter valued at about $60,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock valued at $61,000 after purchasing an additional 4,098 shares during the period. Institutional investors and hedge funds own 48.03% of the company's stock.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 10,778 shares of company stock valued at $58,548 over the last three months. 4.53% of the stock is owned by corporate insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.